As shown in Figure 1H, the combination of MEK inhibitor and CDK4/6 inhibitor was more effective in limiting colony formation and cell growth than MEK inhibitor monotherapy in the majority of the 11 KRAS mutant CRC cell lines assayed. Here, KRAS is linked to colorectal carcinoma.